Logo image
Se connecter
Retour
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Article de revue   Avec comité de lecture

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Riccardo Lencioni, Robert Montal, Ferran Torres, Joong-Won Park, Thomas Decaens, Jean-Luc Raoul, Masatoshi Kudo, Charissa Chang, José Ríos, Valérie Boige, …
Journal of Hepatology, Vol.66(6), pp.1166 - 1172
06/2017
DOI: https://doi.org/10.1016/j.jhep.2017.01.012
PMID: 28131794

Résumé

Response evaluation criteria in solid tumours Surrogate end-point Objective response Liver cancer hepatocellular Carcinoma mRECIST Brivanib Advanced BCLC
The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate whether objective response by mRECIST accurately predicted overall survival (OS) in patients with advanced HCC treated with systemic targeted therapies and also to preliminarily assess this end-point as a potential surrogate of OS.

Fichiers et liens (1)

url
Find in HALAfficher

Indicateurs

1 Consultations de la notice

Détails

Logo image